|
Delayed
Nasdaq
14:40:28 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 2.020 USD | +1.51% |
|
-7.34% | -77.18% |
Company Valuation: Atossa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 19.86 | - | - |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -73.94% | - | - |
| Enterprise Value (EV) | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 19.86 | 19.86 | 19.86 |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -73.94% | 0% | 0% |
| P/E | -8.89x | -2.52x | -3.67x | -4.72x | -2.19x | -0.52x | -0.63x | 0.73x |
| PBR | 1.47x | 0.57x | 1.22x | 1.69x | 1.92x | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.3x | -0.1x | 0.11x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 0.17x |
| EV / Revenue | - | - | - | - | - | - | - | 0.17x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.55x | -0.52x | 0.4x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.7 | -3.15 | -3.6 | -3 | -4.04 | -3.84 | -3.143 | 2.715 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 118.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.52 | -27.69 | -31.38 | -27.62 | -37.14 | -35.88 | -38.03 | 49.46 |
| Net income 1 | -20.61 | -26.96 | -30.09 | -25.5 | -34.77 | -34.89 | -38.03 | 49.46 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 24.000 | 7.927 | 13.200 | 14.161 | 8.850 | 1.990 | 1.990 | 1.990 |
| Nbr of stocks (in thousands) | 8,442 | 8,442 | 8,354 | 8,387 | 8,611 | 9,979 | - | - |
| Announcement Date | 2/28/22 | 3/22/23 | 4/1/24 | 3/25/25 | 3/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.52x | - | - | - | 19.86M | |
| 20.87x | 7.45x | 14.96x | 1.42% | 71.53B | |
| 31.24x | 9x | 28.05x | 0.04% | 60.12B | |
| 34.13x | 6.11x | 18.31x | 0.95% | 48.85B | |
| 34.64x | 3.34x | 14.41x | -.--% | 44.28B | |
| -21.08x | 228.26x | -22.72x | -.--% | 43.83B | |
| 47.85x | 5.53x | 30.37x | -.--% | 41.53B | |
| 27.07x | 7.8x | 20.09x | 0.42% | 30.13B | |
| 32.39x | 6.91x | 17.94x | -.--% | 27.98B | |
| -70.94x | 13.62x | -69.42x | -.--% | 25.25B | |
| Average | 13.56x | 32.00x | 5.78x | 0.32% | 39.35B | |
| Weighted average by Cap. | 19.23x | 31.83x | 9.93x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATOS Stock
- Valuation Atossa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
